Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia

Leukemia Research

Volumn 39, Issue 12, 2015, Pages 1312-1318

  Zeidner, Joshua F ^a   Karp, Judith E ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Alvocidib; CDK inhibitors; Cyclin dependent kinase; FLAM; Flavopiridol

Indexed keywords

CYCLIN D1; CYTARABINE; DAUNORUBICIN; FLAVOPIRIDOL; HIGH MOBILITY GROUP A PROTEIN; MESSENGER RNA; MITOXANTRONE; PROTEIN BCL 2; PROTEIN MCL 1; RNA POLYMERASE II; STAT3 PROTEIN; TRANSCRIPTION FACTOR E2F1; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; FLAVONOID; MCL1 PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; TUMOR MARKER; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; HYPERBILIRUBINEMIA; MONOTHERAPY; NEUTROPENIA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME; TUMOR LYSIS SYNDROME; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CYCLE; CHEMICAL STRUCTURE; DRUG EFFECTS; DRUG INTERACTION; DRUG SCREENING; ENZYMOLOGY; LEUKEMIA, MYELOID, ACUTE; MOLECULARLY TARGETED THERAPY; SALVAGE THERAPY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CELL CYCLE; CYCLIN-DEPENDENT KINASES; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASM PROTEINS; PIPERIDINES; PROTEIN KINASE INHIBITORS; SALVAGE THERAPY; TUMOR LYSIS SYNDROME;

EID: 84951310166     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.10.010     Document Type: Review

References (50)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
2. Rai K.R., Holland J.F., Glidewell O.J., Weinberg V., Brunner K., Obrecht J.P. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981, 58:1203-1212.
3. Yates J., Glidewell O., Wiernik P., Cooper M.R., Steinberg D., Dosik H. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982, 60:454-462.
4. Preisler H., Davis R.B., Kirshner J., Dupre E., Richards F., Hoagland H.C., et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 1987, 69:1441-1449.
5. Appelbaum F.R., Gundacker H., Head D.R., Slovak M.L., Willman C.L., Godwin J.E., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
6. Mrozek K., Marcucci G., Nicolet D., Maharry K.S., Becker H., Whitman S.P., et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J. Clin. Oncol. 2012, 30:4515-4523.
7. Forman S.J., Rowe J.M. The myth of the second remission of acute leukemia in the adult. Blood 2013, 121:1077-1082.
8. Senderowicz A.M., Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 2000, 92:376-387.
9. Bible K.C., Kaufmann S.H. Flavopiridol a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 1996, 56:4856-4861.
10. Decker R.H., Dai Y., Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ. 2001, 8:715-724.
11. Gojo I., Zhang B., Fenton R.G. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res. 2002, 8:3527-3538.
12. Yu C., Rahmani M., Dai Y., Conrad D., Krystal G., Dent P. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res. 2003, 63:1822-1833.
13. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., Worland P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996, 56:2973-2978.
14. Worland P.J., Kaur G., Stetler-Stevenson M., Sebers S., Sartor O., Sausville E.A. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. correlation with decreased H1 kinase activity. Biochem. Pharmacol. 1993, 46:1831-1840.
15. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
16. Sedlacek H.H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 2001, 38:139-170.
17. Kaur G., Stetler-Stevenson M., Sebers S., Worland P., Sedlacek H., Myers C., et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. 1992, 84:1736-1740.
18. Chao S.H., Fujinaga K., Marion J.E., Taube R., Sausville E.A., Senderowicz A.M., et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 2000, 275:28345-28348.
19. Chao S.H., Price D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 2001, 276:31793-31799.
20. Karp J.E., Ross D.D., Yang W., Tidwell M.L., Wei Y., Greer J. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin. Cancer Res. 2003, 9:307-315.
21. Mayer F., Mueller S., Malenke E., Kuczyk M., Hartmann J.T., Bokemeyer C. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest. New Drugs 2005, 23:205-211.
22. Chen R., Keating M.J., Gandhi V., Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005, 106:2513-2519.
23. Burke P.J., Karp J.E., Braine H.G., Vaughan W.P. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res. 1977, 37:2138-2146.
24. Geller R.B., Burke P.J., Karp J.E., Humphrey R.L., Braine H.G., Tucker R.W. A two-step timed sequential treatment for acute myelocytic leukemia. Blood 1989, 74:1499-1506.
25. Karp J.E., Passaniti A., Gojo I., Kaufmann S., Bible K., Garimella T.S., et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin. Cancer Res. 2005, 11:8403-8412.
26. Karp J.E., Smith B.D., Levis M.J., Gore S.D., Greer J., Hattenburg C., et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin. Cancer Res. 2007, 13:4467-4473.
27. Stone R.M., Mazzola E., Neuberg D., Allen S.L., Pigneux A., Stuart R.K., et al. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J. Clin. Oncol. 2015, 33:1252-1257.
28. Fernandez H.F., Sun Z., Yao X., Litzow M.R., Luger S.M., Paietta E.M., et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 2009, 361:1249-1259.
29. Lowenberg B., Ossenkoppele G.J., van Putten W., Schouten H.C., Graux C., Ferrant A., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 2009, 361:1235-1248.
30. Karp J.E., Blackford A., Smith B.D., Alino K., Seung A.H., Bolanos-Meade J., et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk. Res. 2010, 34:877-882.
31. Byrd J.C., Lin T.S., Dalton J.T., Wu D., Phelps M.A., Fischer B., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109:399-404.
32. Blum W., Phelps M.A., Klisovic R.B., Rozewski D.M., Ni W., Albanese K.A., et al. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 2010, 95:1098-1105.
33. Karp J.E., Smith B.D., Resar L.S., Greer J.M., Blackford A., Zhao M., et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011, 117:3302-3310.
34. Nelson D.M., Joseph B., Hillion J., Segal J., Karp J.E., Resar L.M. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk. Lymphoma 2011, 52:1999-2006.
35. Karp J.E., Garrett-Mayer E., Estey E.H., Rudek M.A., Smith B.D., Greer J.M., et al. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica 2012, 97:1736-1742.
36. Litzow M.R., Wang X.V., Carroll M.P., Karp J.E., Ketterling R., Kaufmann S.H., et al. A randomized Phase II trial of three novel regimens for relapsed/refractory acute myeloid leukemia (AML) demonstrates encouraging results with a flavopiridol-based regimen: results of eastern cooperative oncology group (ECOG) trial E1906. Blood 2014, 124(Suppl). Abstract 3742.
37. Zeidner J.F., Foster M.C., Blackford A.L., Litzow M.R., Morris L.E., Strickland S.A., et al. Randomized multicenter phase 2 study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7 + 3) in newly diagnosed acute myeloid leukemia. Haematologica 2015, 100:1172-1179.
38. Lancet J.E., Cortes J.E., Hogge D.E., Tallman M.S., Kovacsovics T.J., Damon L.E., et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014, 123:3239-3246.
39. Blum K.A., Ruppert A.S., Woyach J.A., Jones J.A., Andritsos L., Flynn J.M., et al. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia 2011, 25:1444-1451.
40. Ji J., Mould D.R., Blum K.A., Ruppert A.S., Poi M., Zhao Y., et al. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin. Cancer Res. 2013, 19:1269-1280.
41. Smith B.D., Warner S.L., Whatcott C., Siddiqui-Jain A., Bahr B., Dettman E., et al. An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL-1 expression and function. J. Clin. Oncol. 2015, (Suppl. 5s):33. Abstract 7062.
42. Del Gaizo Moore V., Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013, 332:202-205.
43. Liu W., Deng L., Song Y., Redell M. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS One 2014, 9:e98270.
44. Coude M.M., Braun T., Berrou J., Dupont M., Bertrand S., Masse A., et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget 2015, 6:17698-17712.
45. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
46. Smith C.C., Shah N.P. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am. Soc. Clin. Oncol. Educ. Book 2013, 313-318.
47. Zeidner J.F., Foster M.C. Immunomodulatory drugs: IMiDs in acute myeloid leukemia (AML). Curr. Drug Targets 2015, [Epub ahead of print].
48. Knaus H.A., Kanakry C.G., Luznik L., Gojo I. Immunomodulatory drugs II: immune checkpoint agents in acute leukemia. Curr. Drug Targets 2015, [Epub ahead of print].
49. Buckley S.A., Walter R.B. Update on antigen-specific immunotherapy of acute myeloid leukemia. Curr. Hematol. Malig. Rep. 2015, 10:65-75.
50. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-Andre V., Sigova A.A., et al. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.